Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2019
2019 World Conference on Lung Cancer
Access to all presentations that occur during the 2019 World Conference on Lung Cancer in Barcelona, Spain
Presentation Date(s):- Sept 7 - 10, 2019
- Total Presentations: 2848
To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.
Presentations will be available 24 hours after their live presentation time
-
+
OA04 - Immuno Combinations and the Role of TMB
- Type: Oral Session
- Track: Immuno-oncology
- Presentations: 1
- Now Available
- Moderators:Solange Peters
- Coordinates: 9/08/2019, 15:15 - 16:45, Copenhagen (1980)
-
+
OA04.02 - CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC (Now Available)
15:25 - 15:35 | Presenter: Fabrice Barlesi
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P2.04 - Immuno-oncology
- Type: Poster Viewing in the Exhibit Hall
- Track: Immuno-oncology
- Presentations: 0
- Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
-
+
P2.04-89 - Neoadjuvant Pembrolizumab in Early Stage Non-Small Cell Lung Cancer (NSCLC): Toxicity, Efficacy, and Surgical Outcomes
10:15 - 10:15 | Presenter: Neal Ready
- Abstract
Loading...
-
+
OA14 - Update of Phase 3 Trials and the Role of HPD
- Type: Oral Session
- Track: Immuno-oncology
- Presentations: 0
- Moderators:Julie R Brahmer
- Coordinates: 9/10/2019, 11:30 - 13:00, Vienna (2016)
-
+
OA14.04 - Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC
12:00 - 12:10 | Presenter: Scott Gettinger
- Abstract
Loading...